Literature DB >> 9288633

Characteristics of pain following intracavernous injection of prostaglandin E1.

S C Kim1, S W Lee, K K Seo.   

Abstract

The aim of this study was to determine the incidence and characteristics of pain following intracavernous injection of prostaglandin E1 (PGE). We injected PGE into the cavernous tissues of 156 patients with erectile dysfunction who had never previously been injected with PGE. The incidence and characteristics of pain after injection were evaluated by the patients' response to a questionnaire. The intensity of pain was determined by the degree of impediment to intercourse, verbal rating scale (VRS), numerical rating scale (NRS), and visual analogue scale (VAS). Patients scoring 'no pain' on the VRS, NRS, and VAS were 11.5%, 7.7%, and 7.7%, respectively. Overall incidence of pain was 91%. There was 'much' or 'very much' impediment to intercourse because of pain in 14 (9.1%) patients. The most common kind of pain was 'heavy pain' in 90% of the patients followed by 'throbbing' in 38%, 'aching' in 21%, 'tightening' in 18%, and 'shooting' in 13%. The mean duration of pain was 101.2 +/- 63.7 minutes and it lasted during the entire erection period in 71(50.4%) patients. There were significant correlations among the degree of impediment to intercourse, VRS, NRS, and VAS scores (all p < 0.01). However, no association was noted between pain intensity and both erectile response to PGE and injected dose. The higher incidence of intracavernous PGE-induced pain reported here compared to other studies might be related to difference in pain thresholds among races. The high incidence of pain but low frequency of much impediment to intercourse would be related to the pain characteristics as well as the intensity of pain.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9288633      PMCID: PMC3054211          DOI: 10.3346/jkms.1997.12.4.327

Source DB:  PubMed          Journal:  J Korean Med Sci        ISSN: 1011-8934            Impact factor:   2.153


  1 in total

1.  Is it worth continuing sexual rehabilitation after radical prostatectomy with intracavernous injection of alprostadil for more than 1 year?

Authors:  René Yiou; Zentia Bütow; Juliette Parisot; Michele Binhas; Odile Lingombet; Deborah Augustin; Alexandre de la Taille; Etienne Audureau
Journal:  Sex Med       Date:  2015-03       Impact factor: 2.491

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.